

Table 6. Clinical Trials of GP IIb/IIIa Inhibitors

AGENT	NAME	SETTING	OUTCOME	N	ARD	NNT	RRR
Abciximab (ReoPro)	RAPPORT ⁵⁶	AMI angioplasty	30 d death, MI, TVR	483	5.4%	19	48%
	ISAR-2 ⁵⁷	AMI PCI	30 d death, MI, TVR	401	5.5%	18	53%
	ADMIRAL ⁵⁸	AMI PCI	30 d death, MI, TVR	300	8.6%	12	59%
	ACE ⁵⁹	AMI PCI	30 d death, MI, TVR	400	6%	17	57%
	EPIC ⁶¹	High-risk PCI	30 d death, MI, TVR	2099	4.5%	22	35%
	EPILOG ⁶²	PCI	30 d death, MI, TVR	2792	6.3%	16	54%
	EPISTENT ⁶³	ACS PCI	6 mo death, MI	2399	5.8%	17	53%
	CAPTURE ⁶⁴	UA PCI	30 d death, MI, TVR	1265	4.6%	22	29%
Eptifibatide (Integrilin)	PURSUIT ⁶⁷	High-risk ACS	30 d death, MI	10948	1.5%	67	10%
	IMPACT II ⁶⁸	PCI	30 d death, MI, TVR	4010	2.5%	40	22%
	ESPRIT ⁶⁹	PCI	30 d death, MI, TVR	2064	3.7%	27	36%
Tirofiban (Aggrastat)	RESTORE ⁷⁰	ACS PCI	30 d death, MI, TVR	2139	1.9%	53	16%
	PRISM ⁷¹	ACS	30 d death, MI, ischemia	3232	NS		NS
			30 d death		1.3%	77	36%
	PRISM-PLUS ⁷²	ACS	30 d death, MI, ischemia	1915	3.8%	23	22%
	ADVANCE ⁷³	High-risk PCI	6 month death, MI, TVR	202	15%	7	49%